H.Lundbeck (OTCPK:HLUYY) isn't going to be an especially familiar name for many readers, as this Danish pharmaceutical company has largely sold through licensing partners in the United States. That said, this CNS specialist was the brains behind Forest Labs' (NYSE:FRX) highly successful depression drug Lexapro, and the company has some particularly interesting drugs in its pipeline. While the company's go-to-market strategy is still a work in progress and patent expirations are likely going to cut deeply into cash flows in the short term, this looks like a potentially undervalued name to consider.
Q4 Shows The High Price Of Transition
Lundbeck had an interesting fourth quarter, and one that got worse as you worked down the income...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|